| Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity B Meng, A Abdullahi, IATM Ferreira, N Goonawardane, A Saito, I Kimura, ... Nature 603 (7902), 706-714, 2022 | 1123* | 2022 |
| Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation A Saito, T Irie, R Suzuki, T Maemura, H Nasser, K Uriu, Y Kosugi, ... Nature 602 (7896), 300-306, 2021 | 673* | 2021 |
| Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant R Suzuki, D Yamasoba, I Kimura, L Wang, M Kishimoto, J Ito, Y Morioka, ... Nature 603 (7902), 700-705, 2022 | 647 | 2022 |
| SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity C Motozono, M Toyoda, J Zahradnik, A Saito, H Nasser, TS Tan, I Ngare, ... Cell host & microbe 29 (7), 1124-1136. e11, 2021 | 603* | 2021 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2 spike D Yamasoba, I Kimura, H Nasser, Y Morioka, N Nao, J Ito, K Uriu, ... Cell 185 (12), 2103-2115, 2022 | 394* | 2022 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2 subvariants including BA. 4 and BA. 5 I Kimura, D Yamasoba, T Tamura, N Nao, T Suzuki, Y Oda, S Mitoma, J Ito, ... Cell, 2022 | 283* | 2022 |
| Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants T Tamura, J Ito, K Uriu, J Zahradnik, I Kida, Y Anraku, H Nasser, M Shofa, ... Nature communications 14 (1), 2800, 2023 | 270 | 2023 |
| Recurrent HIV-1 Integration at the BACH2 Locus in Resting CD4+ T Cell Populations during Effective Highly Active Antiretroviral Therapy T Ikeda, J Shibata, K Yoshimura, A Koito, S Matsushita The Journal of infectious diseases 195 (5), 716-725, 2007 | 145 | 2007 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2.75 variant A Saito, T Tamura, J Zahradnik, S Deguchi, K Tabata, Y Anraku, I Kimura, ... Cell host & microbe 30 (11), 1540-1555. e15, 2022 | 136 | 2022 |
| The local dinucleotide preference of APOBEC3G can be altered from 5′-CC to 5′-TC by a single amino acid substitution A Rathore, MA Carpenter, Ö Demir, T Ikeda, M Li, NM Shaban, EK Law, ... Journal of molecular biology 425 (22), 4442-4454, 2013 | 116 | 2013 |
| Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity EW Refsland, JF Hultquist, EM Luengas, T Ikeda, NM Shaban, EK Law, ... PLoS genetics 10 (11), e1004761, 2014 | 114 | 2014 |
| Intrinsic immunity against retrotransposons by APOBEC cytidine deaminases A Koito, T Ikeda Frontiers in microbiology 4, 28, 2013 | 114 | 2013 |
| Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA. 2.86 variant K Uriu, J Ito, Y Kosugi, YL Tanaka, Y Mugita, Z Guo, AA Hinay, O Putri, ... The Lancet Infectious Diseases, 2023 | 112 | 2023 |
| Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ. 1.1 variant J Ito, R Suzuki, K Uriu, Y Itakura, J Zahradnik, KT Kimura, S Deguchi, ... Nature communications 14 (1), 2671, 2023 | 112 | 2023 |
| Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons T Ikeda, KH Abd El Galil, K Tokunaga, K Maeda, T Sata, N Sakaguchi, ... Nucleic acids research 39 (13), 5538-5554, 2011 | 81 | 2011 |
| The antiretroviral potency of APOBEC1 deaminase from small animal species T Ikeda, T Ohsugi, T Kimura, S Matsushita, Y Maeda, S Harada, A Koito Nucleic acids research 36 (21), 6859-6871, 2008 | 57 | 2008 |
| Virological characteristics of the SARS-CoV-2 BA. 2.86 variant T Tamura, K Mizuma, H Nasser, S Deguchi, M Padilla-Blanco, Y Oda, ... Cell Host & Microbe, 2023 | 51 | 2023 |
| Lethal interactions of SARS-CoV-2 with graphene oxide: implications for COVID-19 treatment M Fukuda, MS Islam, R Shimizu, H Nasser, NN Rabin, Y Takahashi, ... ACS Applied Nano Materials 4 (11), 11881-11887, 2021 | 50 | 2021 |
| HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G T Ikeda, M Symeonides, JS Albin, M Li, M Thali, RS Harris PLoS pathogens 14 (4), e1007010, 2018 | 49 | 2018 |
| Virological characteristics of the SARS-CoV-2 Omicron XBB. 1.5 variant T Tamura, T Irie, S Deguchi, H Yajima, M Tsuda, H Nasser, K Mizuma, ... Nature Communications 15 (1), 1176, 2024 | 48 | 2024 |
Reuben S HarrisProfessor of Biochemistry and Structural Biology, HHMI and University of Texas Health San AntonioBestätigte E-Mail-Adresse bei uthscsa.edu
